tbuckley/cabot-search huggingface dataset:
Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials
Authors: G. M. Mead, S. D. Fosså, R. T. Oliver, P. J. Fogarty, P. Pollock, S. P. Stenning
Journal: Journal of Clinical Oncology (2008)

5020 Background: Three MRC randomised non-inferiority trials of adjuvant therapy for stage I seminoma, carried out between 1989 and 1991, have been updated to investigate the risk of late relapse and the method of detection of relapse. Methods: TE10 (JCO 17: 1146–1154, 1999) randomised 478 patients (pts) to 30Gy dog-leg (DL) or para-aortic (PA) irradiation (RT); TE18 (EORTC 30942, JCO 23:1200–1208, 2005) and TE19 collectively randomised 1,094 pts between 30Gy or 20Gy, with PA (89%) or DL(11%) RT at clinicians’ discretion. TE19 (EORTC 30982, Lancet 366: 293–300, 2005) alone compared RT with single-dose carboplatin (C) at AUC7. All trials required chest, abdominal and pelvic CT scans at 1, 2 and 3 yrs. Long-term follow-up (FU) data were sought; relapse-free rates (RFR) were determined by the Kaplan-Meier method, and hazard ratios (HR) from the Cox regression model (HR >1 favors standard treatment). Results: Median FU times, % followed to death or a documented minimum of 5 yrs, 5 yr RFR and HRs are as follows: TE10, 11 yrs, 80%, 96.1% (PA) and 96.2% (DL), HR 1.15 (90% CI 0.54–2.44); TE18, 7 yrs, 84%, 95.1% (30Gy) and 97.0% (20Gy), HR 0.59 (90% CI 0.35–0.99); TE19, 6.5 yrs, 78%, 5-yr RFR 96.0% (RT) and 94.7% (C), HR=1.25 (90% CI 0.83–1.89). A total of 106 pts relapsed after treatment, of whom 4 died of seminoma. Relapse sites differed by treatment, with abdominal relapses most common with C and pelvic most common with PA RT. 4 relapses occurred after 3 years (at 50 (C), 61, 64 and 91 months (RT)), all were disease free after chemotherapy. Details of the first sign prompting relapse diagnosis was available in TE19, and shows a difference between RT and C with 58% and 22% respectively detected by symptoms, and 17% and 61% respectively by CT; <2% of relapses were detected by the 3 yr CT. Conclusions: Long-term FU confirms the original conclusions of the 3 randomised trials. Relapse patterns differed between PA and DL RT and C. Abdominal CT is required for 2 years after C. Late relapse was rare and prolonged follow up after adjuvant treatment unnecessary Site and time of relapse by treatment Treatment Relapse site (% of total) Months to relapse patients relapses multiple abdomen pelvis other min med max PA RT 1470 57 23 8 34 36 4 16 91 DL RT 423 20 12 6 6 76 4 17 36 C 573 29 26 67 0 7 4 25 50 NB: combined data from 3 trials, rows do not reflect randomised arms Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Medical Research Council
Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study
Authors: Martin Pule, Sara Ghorashian, Laura Clifton-Hadley, Paul Smith, Soraya Saiagh, Paul Veys, Nicholas Goulden, Gary Wright, Ettore Biagi, Bianca Altvater, Brigitte Dreno, Kim Champion, Michelle Cummins, Rachael Hough, Martin G. Sauer, Claudia Rossig, Persis Amrolia
Journal: Blood (2014)
Procedural Volume and Outcomes of Septal Reduction Therapies in Patients With Hypertrophic Obstructive Cardiomyopathy
Authors: Sidakpal S. Panaich, Ankit Chothani, Apurva O. Badheka
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
TCT-319 Association Between Endothelial Progenitor Cells And Atherosclerotic Plaque Burden In Stable Coronary Artery Disease: An OCT Study 6-Months After Stent Implantation
Authors: Sylvia Otto, Johannes Gassdorf, Kristina Nitsche, Christian Jung, Juan Luis Gutiérrez-Chico, Bjoern Goebel, Hans R. Figulla, Tudor C. Poerner
Journal: Journal of the American College of Cardiology (2015)
TCT-186 Impact of the number of chronic totally occluded arteries on long-term prognosis in patients with non-ST-segment elevation myocardial infarction treated with percutaneous coronary intervention
Authors: Pawel Gasior, Michal Hawranek, Piotr Desperak, Marek Gierlotka, Mateusz Tajstra, Jacek Piegza, Aneta Cislak, Lukasz Pyka, Andrzej Lekston, Lech Polonski, Mariusz Gasior
Journal: Journal of the American College of Cardiology (2015)
Non-invasive visualization of mast cell recruitment and its effects in lung cancer by optical reporter gene imaging and glucose metabolism monitoring
Authors: Seul-Gi Oh, Xian Li, Ho Won Lee, Thoudam Debraj Singh, Sang Bong Lee, Hyun Dong Ji, GhilSuk Yoon, Sung Jin Cho, In-Kyu Lee, Shin Young Jeong, Byeong-Cheol Ahn, Jaetae Lee, Hyeun Wook Chang, Sang-Woo Lee, Yong Hyun Jeon
Journal: Biomaterials (2016)
Expression of forkhead-box protein A1 (FOXA1) as a significant prognostic and predictive marker for ER-positive breast cancer.
Authors: E. Tokunaga, Y. Hisamatsu, S. Okada, N. Yamashita, Y. Nakashima, H. Saeki, Y. Emi, M. Morita, Y. Kakeji, Y. Maehara
Journal: Journal of Clinical Oncology (2010)

608 Background: One of the major issues associated with the breast cancer therapy is how to determine the indication of adjuvant chemotherapy for the patients with luminal subtypes. Multigene prognosis assays such as Oncotype Dx are excellent techniques, however, there are some limitations in their clinical use, high cost and patent problems. The transcription factor network composed of ER, Forkhead-box protein A1 (FOXA1), and GATA-binding protein 3 (GATA3) is necessary for the ERα functional signature specific to luminal type, and the presence of an intact GATA-3/FOXA1/ ER network appears to be critical for the hormone responsive phenotype. This study evaluated the usefulness of the expression of FOXA1 as a prognostic and predictive marker for ER-positive breast cancer. Methods: We analyzed the expression of FOXA1, GATA3 by immunohistochemical analyses in 155 cases of primary breast cancer. We evaluated the association of the expression of these proteins with clinicopathologic characteristics and prognosis, especially in ER-positive cases. Results: (1) FOXA1 and GATA3 expressions correlated positively (p < 0.0001). (2) FOXA1 expression was positively correlated with ER (p < 0.0001) and PR (p = 0.0003), and inversely correlated with nuclear grade (p = 0.0004) and Ki 67 index (p < 0.0001). (3) FOXA1 expression was significantly correlated with the better prognosis in all (p = 0.0104) and in ER-positive cases (p = 0.0031), but no relationship in ER-negative cases. In addition, low FOXA1 expression was significantly associated with the shorter disease-free survival in patients who received adjuvant endocrine therapy (p = 0.0105). On the other hand, Ki-67 index was associated with the poor prognosis, especially in ER-negative cases, not in ER-positive cases. Conclusions: FOXA1 expression is significantly associated with the good prognosis, especially in ER-positive breast cancer. This study suggests that FOXA1 expression may be used as a prognostic and predictive marker for ER-positive breast cancer, which can be used as a more cost-effective strategy to select the patients in whom chemotherapy may be omitted. No significant financial relationships to disclose.
TCT-514 Absorb Vs DESolve: an optical coherence tomography comparison of acute mechanical performances
Authors: Alessio Mattesini, Niklas Boeder, Katja Löblich, Serafina Valente, Nicolas Foin, Gianluca Caiazzo, Matteo Ghione, Gian Franco Gensini, Porto Italo, Carlo Di Mario, Holger Nef
Journal: Journal of the American College of Cardiology (2015)
Interim-PET Scan Interpretation In the Ongoing Prospective Clinical Trial HD 0607, In Advanced-Stage Hodgkin Lymphoma: Results of the the Expert Panel Review
Authors: Andrea Gallamini, Alberto Biggi, Stephane Chauvie, Alexandru Stancu, Federico Fallanca, Agostino Chiaravalloti, Michele Gregianin, Umberto Ficola, Ugo Guerra, Maria Rosaria Mennitto, Alessandro Rambaldi
Journal: Blood (2010)
TCT-40 Image-Based Computation of Instantaneous Wave-free Ratio from Routine Coronary Angiography - Initial Validation by Invasively Measured Coronary Pressures
Authors: Lucian Calmac, Rodica Niculescu, Elisabeta Badila, Emma Weiss, Diana Zamfir, Lucian Itu, Laszlo Lazar, Marius Carp, Alexandru Itu, Constantin Suciu, Tiziano Passerini, Puneet Sharma, Bogdan Georgescu, Dorin Comaniciu
Journal: Journal of the American College of Cardiology (2015)
TCT-357 Ex-vivo Validation of Vascular Response after Drug-eluting Stent implantation on Coronary Angioscopy
Authors: Masahiko Shibuya, Kenichi Fujii, Hiroyuki Hao, Kenji Kawai, Takahirio Imanaka, Ten Saita, Seiichi Hirota, Tohru Masuyama, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2015)
Simultaneous Reconstitution of Multiple CMV-Specific CD8+ T-Cell Populations with Divergent Functionality in Hematopoietic Stem Cell Transplant Recipients.
Authors: Simon F. Lacey, Joy Martinez, Ghislaine Gallez-Hawkins, Lia Thao, Jeff Longmate, Wahajul Haq, Ricardo Spielberger, Stephen J. Forman, John A. Zaia, Don J. Diamond
Journal: Blood (2004)
Mycophenolate Mofetil Is a Suitable Substitute for Methotrexate for Graft Versus Host Disease Prevention in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Sibling Donors
Authors: Betty K. Hamilton, Lisa Rybicki, Shawnda Tench, Housam Haddad, Brian J. Bolwell, Rabi Hanna, Ronald Sobecks, Robert M Dean, Hien K. Duong, Brian T. Hill, Edward A. Copelan, Matt Kalaycio
Journal: Blood (2012)
Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Authors: Paolo Strati, Hagop M Kantarjian, Aziz Nazha, Gautam Borthakur, Naval G. Daver, Tapan M. Kadia, Zeev Estrov, Guillermo Garcia-Manero, Trivikram Rajkhowa, Farhad Ravandi, Menda Durand, Mark Levis, Jorge E. Cortes
Journal: Blood (2013)
p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer
Authors: Angeles Duran, Eloy D. Hernandez, Miguel Reina-Campos, Elias A. Castilla, Shankar Subramaniam, Sindhu Raghunandan, Lewis R. Roberts, Tatiana Kisseleva, Michael Karin, Maria T. Diaz-Meco, Jorge Moscat
Journal: Cancer Cell (2016)
The IGF1-R Inhibitor AEW541 Is a Potent Anti-Myeloma Agent That Overcomes Drugs Resistance, and Has Synergistic Activity with Other New Drugs.
Authors: Patricia Maiso, Enrique M. Ocio, Mercedes Garayoa, Mark A. Pearson, Atanasio Pandiella, J.F. San Miguel
Journal: Blood (2006)
Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial
Authors: Andreas Hochhaus, Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Muller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Maureen Conlan, Victor M. Rivera, Francois Guilhot, Mochael W. Deininger, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian
Journal: Blood (2015)
Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
Authors: Jo Tomlins, Samar Kulkarni, Clare Rowntree, Nicholas Goulden, Chris Mitchell, Rachael Hough, Sue Richards, Rachel Clack, Adrian JC Bloor, Ajay J Vora
Journal: Blood (2012)
TCT-544 Bioresorbable Coronary Devices in Clinical Practice: Immediate and 30-day Results of the Prospective REPARA Registry
Authors: Felipe Hernandez, Armando Pérez de Prado, Pablo Salinas, Pablo Piñon, Joan Bassaganyas, Alfonso Torres Bosco, Pablo Avanzas, Juan Sanchis, Iñigo Lozano, Jose R. Lopez-Minguez, Koldo Gaviria, Monica Masotti, Leire Andraka, Juan H. Alonso Briales, Raul Moreno, Alberto Berenguer, Pedro Martinez Romero
Journal: Journal of the American College of Cardiology (2015)
A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.
Authors: Tapan M. Kadia, Alessandra Ferrajoli, Farhad Ravandi, Jorge Cortes, Deborah Thomas, William Wierda, Srdan Verstovsek, Willie Newsome, James Zwiebel, Merrill Egorin, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2007)
GW27-e0624 Minimally Invasive Versus Conventional Median Sternotomy in Mitral Valve Repair Patients: a systematic review and meta-analysis
Authors: Xu Zhe, Jin Fan, Mei Jiang, Miao-na Tan, Shao-Hong Ma, Zhi-Ping Wang, Xi Zhang, Jing-Song Ou
Journal: Journal of the American College of Cardiology (2016)
The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors
Authors: Ravi Dashnamoorthy, Nassera Abermil, Afshin Behesti, Paige Kozlowski, Frederick Lansigan, William B Kinlaw, Ronald Gartenhaus, Graham Jones, Lynn Hlatky, Andrew M. Evens
Journal: Blood (2014)
Whole Exome Sequencing of Type 1 and Type 2 Enteropathy-Associated T Cell Lymphoma Reveals Genetic Basis of Eatl Oncogenesis
Authors: Sarah Lynn Ondrejka, Andrea B. Moffitt, Eric Tse, Eric D. Hsi, John R. Goodlad, Rex au-Yeung, Yok-Lam Kwong, Gopesh Srivastava, Randy D. Gascoyne, Deepthi Rajagopalan, Cassandra Love, Sandeep Dave
Journal: Blood (2015)
Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies.
Authors: Shaji Kumar, Noopur Raje, Teru Hideshima, Klaus Podar, Kenji Ishitsuka, Aldo Rocarro, Dharminder Chauhan, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2004)
Impaired Lysophosphatidic Acid Receptor 3 Signaling in Mesenchymal Stromal Cells Promotes Multiple Myeloma Progression through Cellular Senescence and Transdifferentiation into Tumor-Associated Fibroblasts
Authors: Masahiko Kanehira, Tohru Fujiwara, Shinji Nakajima, Yoko Okitsu, Yasushi Ohnishi, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae
Journal: Blood (2015)
Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation: a Single Center Retrospective Study of Risk Factors.
Authors: Hend Ben Neji, Claire Dromer, Reza Tabrizi, Stephane Vigouroux, Herve Guenard, Arnaud Pigneux, Thibaut Leguay, Marie-Sarah Dilhuydy, Krimo Bouabdallah, Anna Schmitt, Gerald Marit, Noel Milpied
Journal: Blood (2010)
TCT-21 Guidewire and Microcatheter Utilization for Antegrade wire escalation in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from a Contemporary Multicenter Registry
Authors: Muhammad Nauman J. Tarar, Georgios E. Christakopoulos, George Christopoulos, Dimitri Karmpaliotis, Khaldoon Alaswad, Robert Yeh, Farouc Jaffer, R. Michael Wyman, William Lombardi, J. Aaron Grantham, David Kandzari, Nicholas Lembo, Jeffrey W. Moses, Ajay J. Kirtane, Manish Parikh, Philip Green, Matthew T. Finn, Santiago Garcia, Anthony H. Doing, Ashish Pershad, Alpesh Shah, Mitul Patel, John Bahadorani, Craig Thompson, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2015)
The primary care provider (<scp>PCP</scp>)‐cancer specialist relationship: A systematic review and mixed‐methods meta‐synthesis
Authors: Lesly A. Dossett, Janella N. Hudson, Arden M. Morris, M. Catherine Lee, Richard G. Roetzheim, Michael D. Fetters, Gwendolyn P. Quinn
Journal: CA A Cancer Journal for Clinicians (2016)

Abstract Although they are critical to models of coordinated care, the relationship and communication between primary care providers (PCPs) and cancer specialists throughout the cancer continuum are poorly understood. By using predefined search terms, the authors conducted a systematic review of the literature in 3 databases to examine the relationship and communication between PCPs and cancer specialists. Among 301 articles identified, 35 met all inclusion criteria and were reviewed in‐depth. Findings from qualitative, quantitative, and disaggregated mixed‐methods studies were integrated using meta‐synthesis. Six themes were identified and incorporated into a preliminary conceptual model of the PCP‐cancer specialist relationship: 1) poor and delayed communication between PCPs and cancer specialists, 2) cancer specialists' endorsement of a specialist‐based model of care, 3) PCPs' belief that they play an important role in the cancer continuum, 4) PCPs' willingness to participate in the cancer continuum, 5) cancer specialists' and PCPs' uncertainty regarding the PCP's oncology knowledge/experience, and 6) discrepancies between PCPs and cancer specialists regarding roles. These data indicate a pervasive need for improved communication, delineation, and coordination of responsibilities between PCPs and cancer specialists. Future interventions aimed at these deficiencies may improve patient and physician satisfaction and cancer care coordination. CA Cancer J Clin 2017;67:156–169. © 2016 American Cancer Society.
Interim results of the phase II study of vinflunine (VFL) in malignant pleural mesothelioma (MPM)
Authors: D. Talbot, J. Margery, G. Dabuis, G. Dark, H. Taylor, H.-N. Mancha, H. Boussemart, V. Cadic, A. Rivière, P. Ruffié
Journal: Journal of Clinical Oncology (2005)

7171 Background: Vinflunine (Javlor) is a new semi-synthetic fluorinated vinca alkaloid which has shown antitumor activity in second line chemotherapy of advanced NSCLC or in first line treatment when combined with CDDP. Methods: This phase II trial was designed to determine the response rate (RECIST) and the safety (NCI-CTC) of vinflunine given at 320 mg/m2 once every 3 weeks in chemonaive patients (pts) with advanced MPM. Results: From 07/2002 to 07/2004, 67 pts were included into the study. As of today, 55 treated pts are analyzed (42 males, median age 61.8 years), initial stages I-II 16 pts, III-IV 38 pts and unknown 1 pt (epithelioid 85.5 %). Karnofsky performance status were: 100%: 6 pts, 90%: 26 pts, 80% 23 pts. The median number of cycles administered was 3 [1–9] and the median relative dose intensity per cycle was 99.8%. Out of the 55 pts, disease control was achieved in 60% (33 pts), 6 pts achieved a confirmed partial response after external radiological review (response rate: 10.9%, 95% CI: [4.1–22.2]). Four patients are too early for tumour assessment and 2 pts are not evaluable for response. In terms of tolerance, 195 cycles (cy) were analysed; grades (G) 3/4 neutropenia and anaemia were reported in 23 (20.5% of cy) and 1 (0.5% of cy) patients respectively; no > G1 thrombocytopenia was observed; neither febrile neutropenia nor neutropenic infection occurred. Grades 3/4 non-hematological toxicities observed were: fatigue 2 pts, abdominal pain 2 pts; constipation 3 pts, myalgia 1 pt. After peripheral administration (36 pts), 12 of them experienced injection site reactions G1 (6 pts) and G 2 (6 pts). No peripheral neuropathy grades 3/4 was observed. Conclusions: Vinflunine achieved promising overall response rate and significant disease control rate. Furthermore, its good safety profile permits to reach an optimal dose intensity without any deleterious side effects. Final results will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Institut de Recherche Pierre Fabre
GW27-e0586 Identification by targeted exome sequencing of gene defect responsible for young patients with severe hypercholesterolemia
Authors: Jiang Long, Long Jiang, Minhua Wen, Renqiang Yang, Kui Hong, Yanqing Wu, Qinghua Wu, Luya Wang, Xiaoshu Cheng
Journal: Journal of the American College of Cardiology (2016)
TCT-540 Impact of postdilation on procedural and clinical outcomes in long and complex lesions treated with bioresorbable vascular scaffolds- a prospective registry study
Authors: Jiang-Ming Fam, Yoshinobu Onuma, Cordula Felix, Roberto Diletti, Nicolas M. Van Mieghem, Evelyn Regar, Peter De Jaegere, Felix Zijlstra, Robert J. Van Geuns
Journal: Journal of the American College of Cardiology (2015)
Metastasis to the Medial Cuneiform Bone from Squamous Cell Carcinoma of the Lung Revealed by Bone Scintigraphy
Authors: Wei Li, Wen Li, Rusen Zhang
Journal: Clinical Nuclear Medicine (2016)

A 61-year-old man with a history of squamous cell carcinoma of the lung presented with a progressive left foot pain for 7 months. Bone scan was acquired to evaluate possible metastasis, which showed abnormal accumulation of Tc-MDP in the left foot, which was seen in the medial cuneiform bone on SPECT/CT images. Histopathological examination from biopsy specimen confirmed cuneiform bone metastasis from lung squamous carcinoma.
Accuracy of Wrist-Worn Heart Rate Monitors
Authors: Robert Wang, Gordon Blackburn, Milind Desai, Dermot Phelan, Lauren Gillinov, Penny Houghtaling, Marc Gillinov
Journal: JAMA Cardiology (2016)

Accuracy of Wrist-Worn Heart Rate MonitorsWrist-worn fitness and heart rate (HR) monitors are popular. 1,2 While the accuracy of chest strap, electrode-based HR monitors has been confirmed, 3,4 the accuracy of wrist-worn, optically based HR monitors is uncertain. 5,6 Assessment of the monitors' accuracy is important for individuals who use them to guide their physical activity and for physicians to whom these individuals report HR readings.The objective of this study was to assess the accuracy of 4 popular wrist-worn HR monitors under conditions of varying physical exertion.Methods | This study recruited 50 healthy adults.The mean (SD) age was 37 (11.3)years; the mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 23.5 (3.1); 28 participants were women (58%), and 7 participants were African American (14%).Exclusion criteria included cardiovascular disease, pacemakers, and treatment with heart rhythm medications.The protocol was approved by the Cleveland Clinic institutional review board.Participants provided written informed consent.Participants wore standard electrocardiographic limb leads and a Polar H7 chest strap monitor secured tightly to ensure skin contact.Each participant was randomly assigned to wear 2 different wrist-worn HR monitors placed tightly above the ulnar styloid.Four wrist-worn monitors were assessed: Fitbit Charge HR (Fitbit), Apple Watch (Apple), Mio Alpha (Mio Global), and Basis Peak (Basis).Heart rate was assessed with the participant on a treadmill at rest and at 2 mph, 3 mph, 4 mph, 5 mph, and 6 mph.Participants exercised at each setting for 3 minutes to achieve a steady state; HR was recorded instantaneously at the 3-minute point.After completion of the treadmill protocol, HR was recorded at 30, 60, and 90 seconds' recovery.